Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
William J. Peters, the CFO, EVP, and Treasurer of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), recently executed a series of transactions involving the company’s common stock. These transactions come as the stock trades near its 52-week low, with InvestingPro data showing strong fundamentals, including liquid assets exceeding short-term obligations. On March 4, 2025, Peters sold 4,231 shares at an average price of $27.54, totaling approximately $116,515. This sale was conducted under a Rule 10b5-1 trading plan adopted on March 14, 2024.
Additionally, Peters exercised options to acquire 7,490 shares at $13.35 each, amounting to a total value of $99,991. Some of these shares were subsequently withheld to cover tax liabilities, resulting in a transaction worth $48,031 at a price of $27.62 per share.
Following these transactions, Peters holds a total of 95,624 shares directly.
In other recent news, Amphastar Pharmaceuticals reported its fourth-quarter 2024 earnings, which fell short of analyst expectations. The company’s earnings per share (EPS) came in at $0.92, missing the forecasted $0.97, and revenue was reported at $186.5 million, below the expected $192.69 million. Amphastar’s annual revenue, however, showed a 14% increase year-over-year, reaching $732 million. Despite this growth, the company is facing challenges with its gross margins, which decreased to 46.5% from 54% the previous year. Looking forward, Amphastar anticipates flat sales in 2025 but is hopeful for a return to double-digit growth in 2026, with potential approvals for four key products in 2025. The company is also expanding its manufacturing capacity and increasing research and development spending. Additionally, Amphastar has formed a new strategic partnership with MannKind (NASDAQ:MNKD) to enhance the sales reach of Baximy, a move expected to bolster its position in the diabetes care market. These developments reflect Amphastar’s ongoing efforts to navigate competitive pressures and maintain its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.